ARTICLE | Company News
Ipsen, 3B Pharmaceuticals deal
February 29, 2016 8:00 AM UTC
3B granted Ipsen exclusive, worldwide rights to develop and commercialize radiopharmaceuticals targeting the neurotensin (NTS) receptor. Ipsen will develop the preclinical compounds to treat pancreat...